Skip to main content
OncoPrescribe
  • HOME
  • WHY US
  • ABOUT
  • SIGN IN
  • SIGN UP

Top Ad

OncoPrescribe-SI

Advertisement

BELEODAQ® (Belinostat)

July 24, 2014May 6, 2020 RR FDA Approvals
Non-Hodgkin Lymphoma

The FDA on July 3, 2014 granted accelerated approval to BELEODAQ® for the treatment of patients with relapsed or refractory Peripheral T-Cell Lymphoma (PTCL). BELEODAQ® is a product of Spectrum Pharmaceuticals, Inc.

Related Posts:

  • Belinostat, a novel pan-histone deacetylase inhibitor…

Post navigation

Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer Results of the OPTIMIZE-2 trial
ZYDELIG® (Idelalisib)

Bottom Ad

hem-onc-updates

Advertisement

Subscribe

Subscribe

Ad 1

OncoPrescribe-CDC

Advertisement

Ad 2

”Dictionary-of-Cancer-Terms-in-OncoPrescribe”/

Advertisement

Ad 3

OncoPrescribe-Ad

Advertisement

Ad 4

OncoPrescribe

Advertisement

  • PRIVACY
  • TERMS
  • DISCLAIMER
  • CONTACT
OncoPrescribe, LLC. All Rights Reserved